Here we focused on acute models of nephritis, but future studies will be required to investigate the effect of longer-term HIF1α or glycolysis inhibition in chronic models of nephritis, such as in NZB/W mice, to determine the potential of these therapies for treating patients with lupus nephritis. Here, HIF1A is linked to lupus nephritis.